Skip to main content
Premium Trial:

Request an Annual Quote

NimbleGen Taps Global Business VP; Poste Joins Caris' Board; NextGen Hires Third Wave Alumnus to Run Global Sales; and Others

NEW YORK (GenomeWeb News) — NimbleGen Systems has named Gregory McGuinness to be its vice president of international business, the company said.
 
McGuinness is former director of European business development for Gene Logic, and was director of channel management for Affymetrix and director of sales and distributor relations for Genetic Microsystems. He also worked with Stratagene, PerkinElmer, and Applied Biosystems.


Caris Diagnostics has named George Poste as an outside director to its board of directors, the company said this week.
 
Poste is a senior technical advisor at Caris, which has a controlling stake in Caris Diagnostics.
 
Poste also is director of the Biodesign Institute at Arizona State University, a biotech/nanotech program, and he is chief executive at Health Technology Networks a genomics consulting company.
 
Poste is a fellow of the Royal Society and the UK Academy of Medicine, a distinguished fellow at the Hoover Institution of Stanford University and a member of the Council for Foreign Relations.

 
NextGen has appointed Jake Orville as vice president of global sales, the company said.
 
Orville comes to NextGen from Third Wave Technologies, where as vice president of sales and business development.
 
Orville takes over for Geoff Alms, who moves to a lead role in North American Development.


Gene Express has appointed Colette Saccomanno to be the company's director of business development, the company said today.
 
Saccomanno, who has a sales and marketing background, most recently was program manager at ArisGlobal and was a senior account executive at Galt Associates. She also served as account executive at Covance Laboratories'
Early Development segment, which is now Abbot Molecular, and at Bio-Rad Laboratories.

 
GeneNews has named Roman Zastawny vice president of biomarker development, the company said this week. Zastawny will run product development but will focus on getting the company's ColonSentry ready to take to market.
 
The company said Zastawny has been vice president of R&D at Tm Bioscience, where he led a team to gain FDA clearance for a cystic fibrosis diagnostic, and as vice president of development at Novx Systems, where he worked to get a product cleared by Canadian health officials.

 
Transgenomic has hired Debra Schneider to be the company's vice president and chief financial officer as of Dec. 4, the company said.
 
Schneider comes to Transgenomic from First Data Corporation, where for 17 years she worked in various capacities, including serving as CFO for business interests and as vice president of finance.

 
Sigma-Aldrich's board of directors elected Steven Paul to be a company director, Sigma said this week.
 
Paul currently is executive vice president for science and technology and president of the Lily Research Laboratories of Eli Lilly.
 
Before working at Eli Lilly Paul served as scientific director of the National Institutes of Health.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.